Author: Nicholas Hall Reports
Publishing at the end of November is our new category report: Lifestyle OTCs. It will provide a comprehensive review of a vital part of the OTC industry covering such diverse categories as obesity treatments, smoking control, sedatives & sleep aids, sexual health, eye care, home diagnostics, systemic cardiovasculars and cholesterol reduction.
The report will help to answer a series of question including:
- What are the key trends that will drive eye care sales?
- Is there still a non-Rx future for statins after the failure of OTC Zocor? Can Lipitor switch in the US and create a successful new OTC category?
- What can be learned from the meteoric rise of ZzzQuil among sleep aids?
- What does the rise of e-cigarettes mean for traditional OTC smoking control products?
Chapters:
- Executive Summary
- Eye Care
- Heart Health
- Home Diagnostics
- Sedatives & Sleep Aids
- Sexual Health
- Smoking Control
- Urinary Products
- Weight Loss
- Lifestyle OTCs Outlook
Whether you already have a vested interest in this sector of the OTC market or are curious to find out the trends & opportunities and learn from existing strategies, Lifestyle OTCs will have something for you.
Table of Contents
Executive summary
Eye care
- Overview
- Does the rise of a handful of big-name eye health players foreshadow a consolidation of the category
- Brands for older consumer - a largely unfulfilled niche?
- USA
- Artificial tears
- Eye decongestants
- Contact lens care
- Looking ahead
- Canada
- Artificial tears
- Eye decongestants
- Contact lens care
- France
- Artificial tears
- Eye decongestants
- Eye washes
- Blepharitis treatments
- Homeopathics
- Germany
- Artificial tears
- Eye decongestants
- Italy
- Eye decongestants
- Other eye care segments
- UK
- Brand case study: Optrex
- Other eye care brands
- Spain
- Pure OTC brands expand as semi-ethicals decline
- Russia
- Strongest growth driven by high adspend
- Lower tier brands enjoy a wide range of positionings
- Poland
- Starazolin's meteroic rise to eye care No.1 a result of diversification and focused A+P
- International brands compete for share in a fragmented lower tier
- China
- Strong performances across the category drive a healthy topline
- Japan
- New ingredient launches diversify allergy eye care market
- Dynamism of longline Rohto range drives topline growth
- NPD key to growth in the fragmented lower tier
- Australia
- Established brands drive topline growth
- Lower tier sees significant NPD investment
- India
- South Korea
- Brazil
- Mexico
- Venezuela
- Outlook for eye care
Heart health
- Overview
- Systemic cardiovasculars
- Will aspirin gain expanded indications?
- C&E Europe
- Western Europe
- North America
- Asia-Pacific
- Latin America
- Cholesterol reduction
- Number of people taking Rx statins for cholesterol reduction is increasing at a fast pace
- What is the potential for an OTC cholesterol reduction category based on statins?
- Zocor Heart Pro - a switch failure in the UK
- Lipitor to switch in the US?
- Supplements for health health
- Omega-3 for heart health boosted by positive studies...
- ...However, doubts are raised over their benefits
- Blockbuster Rx omega-3 supplement Lovaza has global
- OTC potential
- Krill oil-based omega-3 supplement MegaRed makes waves
- Important omega-3 launch in Japan
- Co-enzyme Q10 reputation grows thanks to studies
- Do phytosterol supplements for cholesterol reduction have a future?
- Outlook for heart health
Home diagnostics
- Overview
- Blood glucose meters
- North America
- Europe
- Prospects for blood glucose meters
- Blood pressure monitors
- Family planning
- Ovulation tests
- North America
- Europe
- Alternative ovulation tests
- Fertility tests
- Pregnancy tests
- Innovation and technological advances in pregnancy tests
- North America
- Europe
- STD tests
- A lack of OTC options
- Taking the shame out of STD testing
- Urine tests
- Fitness & sleep monitors
Sedatives & sleep aids
- Overview
- What are the chances of Rx insomnia treatments switching OTC?
- USA
- Rx insomnia segment offers potential switches
- Brand case study: ZzzQuil
- Natural sleep aids a significant segment
- Nasal strips losing out to liquid brands and natural options
- Canada
- Nasal strip Breathe Right dominates the category
- Competitive diphenhydramine segment invigorated by ZzzQuil
- Naturals segment faces competition from longline VMS ranges
- Germany
- Baldriparan faces growing competition from dynamic Neurexan
- France
- Natural sleep aids are growing well, but could not offset continued decline of sedatives
- Italy
- Valdispert and Pineal take largest share of fragmented category
- Spain
- Dormidina secures its position at the head of a sluggish category
- UK
- Russia
- Dynamism of Afobazol a key contributor to overall growth
- Poland
- China
- Allopathic segment underdeveloped, with Rx options a barrier
- TCMs continue to grow to challenge Nao Bai Jin
- Japan
- Despite efforts to improve consumer awareness, sales of leading brands remain low
- Australia
- Longline naturals ranges account for majority of sales
- Marketers of medicated brands using alternative methods to promote non-advertisable OTCs
- Wide range of medical devices compete within small anti-snoring segment
- Brazil
- Passiflora brands dominant in a generally dynamic category
- Brand case study: Seakalm
- Mexico
- Outlook for sedatives & sleep aids
Sexual health
- Overview
- Contraception
- Emergency hormonal contraception
- Asia-Pacific
- North America
- Western Europe
- EHC in other key markets
- Prospects for EHC
- Daily oral contraception
- Asian markets provide bulk of (limited) OTC daily OC sales
- Pilot schemes increase availability of DOC in the UK
- Calls in the US to switch DOC
- Prospects for daily Ocs
- Erectile dysfunction
- The OTC potential of ED
- New Zealand makes "first in world" switch of sildenafil
- Viagra's eventual switch seen by many as inevitable
- Developments among the main ED brands
- Sanofi and Eli Lilly plan Cialis OTC launch for 2018
- Pharmacy availability of ED without a prescription in the UK
- China's ED market sees generic Viagra launch
- Marketing for ED skews towards humour ... and a younger demographic
- Prospects for ED treatments
- Chlamydia treatments
- UK alone in offering OTC chlamydia treatment
Smoking control
- Overview
- North America
- Europe
- UK
- France
- Nordic markets
- Germany
- Spain
- Poland
- Russia
- Asia-Pacific
- Australia
- Japan
- China
- India
- South Korea
- Latin America
- Rx smoking control
- E-cigarettes
- Overview
- Impact on current smoking control market
- Regulation of e-cigarettes
- Future of e-cigarettes
- Prospects for OTC smoking control
Urinary products
- Overview
- UTIs
- Cystitis treatments on the up in Europe
- Outside Europe, US is the key market for UTI treatments
- Does switch of antibiotics for UTIs in New Zealand herald new era for OTC treatment?
- Benign prostatic hyperplasia
- OTC treatments for BPH currently limited
- What impact has Flomax Relief's switch in the UK made?
- Overactive bladder
- Outlook for urinary products
Weight loss
- Overview
- Regulatory roundup
- Key global developments
- US weight loss market
- US regulators working to ensure safety and reliability
- Meal replacements and diet plans a significant segment of dietary aids
- MLM a growing presence in the US dietary supplements category
- Weight loss supplements
- Lipase inhibitors
- Xenical is present across certain Asian markets
- Alli's strong launch gives way to disappointing sales period, but recovery is on the cards
- Alli launch process a textbook example of advisory OTC launch
- Marketing strategy emphasises Alli's USP
Lifestyle OTCs outlook
- Global prospects for lifestyle OTCs
- Category prospects
